Qelbree Mechanism and Efficacy

Pharmacological Properties

• Viloxazine functions as a selective norepinephrine reuptake inhibitor with serotonin-norepinephrine modulating properties, representing a nonstimulant treatment option 1, 2

Treatment Guidelines

• The American Academy of Child and Adolescent Psychiatry and other guideline societies may recommend Qelbree as a treatment option for ADHD, although the article does not explicitly state this, it can be inferred that Qelbree is a viable option based on its FDA approval and clinical trial data 1, 2

Dosing and Administration

• Administer Qelbree once daily in the morning for optimal ADHD symptom control throughout the day, as recommended by medical guidelines 3
• Therapeutic effects may not be observed until 2-4 weeks after initiation, though some studies show benefits as early as week 2, according to clinical data 3